Compare NKX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | PHAR |
|---|---|---|
| Founded | 2002 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | NKX | PHAR |
|---|---|---|
| Price | $12.52 | $16.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 109.3K | 22.5K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $24.80 |
| Revenue Next Year | N/A | $6.84 |
| P/E Ratio | ★ N/A | $2,946.57 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $9.78 | $7.50 |
| 52 Week High | $12.00 | $18.12 |
| Indicator | NKX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 51.06 |
| Support Level | $12.43 | $16.23 |
| Resistance Level | $12.80 | $17.00 |
| Average True Range (ATR) | 0.06 | 0.75 |
| MACD | -0.03 | -0.16 |
| Stochastic Oscillator | 24.32 | 36.44 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.